{
    "clinical_study": {
        "@rank": "74025", 
        "arm_group": {
            "arm_group_label": "Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin", 
            "arm_group_type": "Experimental", 
            "description": "Treatment A: Rosuvastatin tablet orally on specified days\nTreatment B: Daclatasvir, Asunaprevir and BMS-791325 Fixed dose combination (FDC) + BMS-791325 tablet orally on specified days\nTreatment C: Daclatasvir, Asunaprevir and BMS-791325 FDC + BMS-791325 + Rosuvastatin tablet orally on specified days"
        }, 
        "brief_summary": {
            "textblock": "The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir\n      (ASV)/BMS-791325 combination therapy on the exposure of Rosuvastatin."
        }, 
        "brief_title": "Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "IND Number: 79,599/101,943\n\n      Primary Purpose: Other -  Phase 1 Clinical Pharmacology drug interaction study in healthy\n      subjects"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Healthy subjects with no clinically significant deviations from normal in medical\n             history, physical exam findings, 12 lead ECG measurements and clinical laboratory\n             tests\n\n          -  Females must be of non-childbearing potential\n\n        Exclusion Criteria:\n\n          -  Women of childbearing potential\n\n          -  Any significant acute or chronic medical condition\n\n          -  Inability to tolerate oral medications\n\n          -  Inability to be venipunctured and/or tolerate venous access\n\n          -  Abnormal liver function tests\n\n          -  Current or recent (within 3 months of dosing) gastrointestinal disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104843", 
            "org_study_id": "AI443-115"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin", 
                "intervention_name": "Daclatasvir, Asunaprevir and BMS-791325 FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin", 
                "intervention_name": "BMS-791325", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Crestor\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 2, 2014", 
        "number_of_arms": "1", 
        "official_title": "Effect of Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Therapy on the Pharmacokinetics of Rosuvastatin", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed concentration (Cmax) of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (predose) to Day 5 (96 hours) and Day 15 (predose) to Day 19 (96 hours)"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (predose) to Day 5 (96 hours) and Day 15 (predose) to Day 19 (96 hours)"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (predose) to Day 5 (96 hours) and Day 15 (predose) to Day 19 (96 hours)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104843"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time of maximum observed concentration (Tmax) of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 15 (predose through 96 hours)"
            }, 
            {
                "measure": "Half life (T-HALF) of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 15 (predose through 96 hours)"
            }, 
            {
                "measure": "Apparent total body clearance (CLT/F) of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 15 (predose through 96 hours)"
            }, 
            {
                "measure": "Maximum observed concentration (Cmax) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose"
            }, 
            {
                "measure": "Trough observed plasma concentration (predose) (Ctrough) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose"
            }, 
            {
                "measure": "Area under the concentration-time curve in one dosing interval [AUC(TAU)] of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose"
            }, 
            {
                "measure": "Time of maximum observed concentration (Tmax) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose"
            }, 
            {
                "measure": "Observed plasma concentration at 12 hours after dosing in a pharmacokinetic (PK) profile (C12) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 15 (predose through 12 hours) and Days 13 and 14 pre-AM-dose"
            }, 
            {
                "measure": "Safety measured by incidence of Adverse events (AEs), Serious adverse events (SAEs) and AEs leading to discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1 through 19"
            }, 
            {
                "measure": "Safety measured by results of vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1 through 19"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}